Protalix BioTherapeutics, Inc.
General ticker "PLX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $156.0M (TTM average)
Protalix BioTherapeutics, Inc. follows the US Stock Market performance with the rate: 6.6%.
Estimated limits based on current volatility of 2.9%: low 2.75$, high 2.92$
Factors to consider:
- Earnings expected soon, date: 2026-03-16 bmo
- Total employees count: 213 (+2.4%) as of 2024
- Top business risk factors: Product development and market acceptance, Regulatory and compliance, Operational and conduct risks, Supply chain disruptions, Market competition
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.52$, 3.31$]
- 2025-12-31 to 2026-12-31 estimated range: [1.81$, 3.70$]
Financial Metrics affecting the PLX estimates:
- Positive: with PPE of 59.5 at the end of fiscal year the price was very low
- Positive: -4.75 < Operating profit margin, % of 7.34
- Positive: 6.64 < Operating cash flow per share per price, % of 6.70
- Positive: Investing cash flow per share per price, % of 3.26 > -0.63
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 3.84
- Negative: negative Industry operating cash flow (median)
Short-term PLX quotes
Long-term PLX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $47.64MM | $65.49MM | $53.40MM |
| Operating Expenses | $60.65MM | $55.03MM | $49.48MM |
| Operating Income | $-13.01MM | $10.46MM | $3.92MM |
| Non-Operating Income | $-1.38MM | $-1.89MM | $0.24MM |
| R&D Expense | $29.35MM | $17.09MM | $12.97MM |
| Income(Loss) | $-14.40MM | $8.57MM | $4.15MM |
| Taxes | $0.53MM | $0.25MM | $1.22MM |
| Profit(Loss)* | $-14.93MM | $8.31MM | $2.93MM |
| Stockholders Equity | $-10.64MM | $33.57MM | $43.21MM |
| Inventory | $16.80MM | $19.05MM | $21.24MM |
| Assets | $55.79MM | $84.43MM | $73.42MM |
| Operating Cash Flow | $-25.00MM | $-1.32MM | $8.67MM |
| Capital expenditure | $0.63MM | $1.15MM | $1.28MM |
| Investing Cash Flow | $-5.04MM | $-16.71MM | $4.22MM |
| Financing Cash Flow | $8.24MM | $24.67MM | $-16.79MM |
| Earnings Per Share** | $-0.31 | $0.12 | $0.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.